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model selection, health states, hypotheses, survival analysis, clinical data sources 
and the treatment of uncertainty. Results: Twelve economic evaluations in oncol-
ogy were submitted to NICE by pharmaceuticals companies (PC) between 2013 and 
2015. Seven PC submitted a MCM, two a PSM, two a semi-markov partitioned sur-
vival model, and one a semi-markov model (SMM). Differences between modeling 
techniques were classified into four items: clinical data sources (e.g. published 
aggregated data for MCM and limited IPD for PSM), structure (e.g calculation of tran-
sition probabilities for MCM), hypotheses (e.g. same transition probability of death 
between two health states for MCM), flexibility of the model (e.g. access to patient 
level data for comparators required in PSM). ConClusions: Being a more flex-
ible modeling technique, Markov models remain more frequently used compared 
to PSM. Nevertheless, PSM represent a more straightforward option when patient 
level data are available but are inappropriate when such data are not accessible 
for comparators.
PRM124
Physicians’ choice as a coMPaRatoR in clinical tRials: challenges 
foR PhaRMacoeconoMic Modelling of innovative tReatMents to 
suPPoRt health technology assessMents
Mbanya Z, Madrigal AM, Wright A
PHMR Ltd, London, UK
objeCtives: To identify specific challenges for modelling to support health tech-
nology assessment (HTA) submissions using trial data where the comparator is the 
physician’s choice (PC). Methods: Most clinical trials are designed globally or inter-
nationally, with minimal consideration of individual market needs. It is increasingly 
common for investigational drugs to be compared against a mix of PC treatments 
because a standard of care (SOC) is not always clearly defined. We searched a clini-
cal trials database for registered trials where PC was the comparator. Based on the 
standard requirements for pharmacoeconomic models to support HTAs, we evaluated 
trial information to identify specific modelling challenges. Results: We found 49 reg-
istered trials using PC as the comparator and identified four specific challenges that 
require guidance from HTA bodies. (1) One or more drugs used in PC regimens may not 
be licensed for an individual market, rendering their use problematical. (2) Comparison 
made against individual PC drugs results in lower patient numbers for comparison, 
reducing analysis credibility. (3) Analysis against individual PC drugs requires breaking 
randomisation, which jeopardises trial design integrity. (4) Involvement of a PC mix 
results in the need for a full incremental analysis, which might lead to application 
rejections in circumstances where the new treatment may only have incremental 
benefits over some of the individual treatments. ConClusions: The use of PC as 
a comparator in clinical trials poses challenges that are likely to slow the process of 
access to effective, innovative treatments. HTA agency involvement early in the life 
cycle of a technology would facilitate a shared understanding of evidence require-
ments. HTA agencies should develop clear guidelines on how PC efficacy and cost 
should be used for pharmacoeconomic modelling.
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evaluation of the effect of cRude leaves extRact of indigofeRa 
sPicata foRssk.(fabaceae) on blood glucose level of noRMoglyceMic, 
oRal glucose loaded and alloxan induced diabetic Rodents
Birru EM
University of Gondar, Gondar, Ethiopia
objeCtives: to evaluate the effect of the hydro-alcoholic leaves crude extract of 
Indigofera spicata(ISP) on the blood glucose level(BGL) of normoglycemic, oral glu-
cose loaded and alloxan induced diabetic rodents. Methods: The animals were 
randomly divided into five groups (n= 6) for all the aforementioned three models. In 
all models, group-I mice provided 2%tween-80, group-II were treated with 5mg/kg 
glibenclamide and the remaining three groups(III, IV &V) were treated with 100, 200, 
and 400mg/kg dose of the extract respectively. Statistical significance of differences 
in BGLs within and between groups was analyzed by SPSS version-21 using one 
way ANOVA followed by Tukey’s post hoc multiple comparison. Results: 200mg/
kg and 400mg/kg extract treated groups of normoglycemic mice showed significant 
(p< 0.05) BGL reduction compared to the pre-exposure level. In case of OGTT model 
BGL reduction was statistically significant (p< 0.05) in only 400mg/kg exposed groups 
at the 120 minute of post-exposure compared to the initial level. However, the BGL 
reducing effect of doses of the extract at the 4th, 6th and 10thhours of post treatment 
on diabetic mice was found statistically significant compared to both the negative 
control(p< 0.001) and their respective pretreatment levels(p< 0.05). ConClusions: 
Generally the crude extract of ISP leaves have shown prominent anti-diabetic effect 
and can be therefore used as a good insight for novel anti-diabetic drug discovery 
and development with a call of further in vitro and in vivo studies.
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Hummel N1, Gsteiger S2
1University of Bern, Bern, Switzerland, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland
objeCtives: To identify and assess disease progression models used in rheumatoid 
arthritis (RA) cost-effectiveness modelling. Methods: We examined all studies 
identified in two recent systematic literature reviews on health economic deci-
sion models evaluating RA treatments. We identified the elements in these studies 
describing disease progression and classified them by outcome measure affected 
and by model type. Results: Disease progression models concern in most cases 
the health assessment questionnaire (HAQ) score. The reported individual sampling 
models and discrete event simulation models make assumptions about improve-
ment of the HAQ when treated, depending on the patient’s type of response (e.g. 
remission, good, moderate or no response, measured by the American College of 
Rheumatology (ACR) response criteria or by the disease activity score 28 (DAS28)). 
Furthermore, they assume a long-term deterioration in the HAQ score and a rebound 
effect when the treatment stops, i.e. for example a complete loss of the initial 
Of 630 articles identified, four studies passed the inclusion criteria, and three were 
included by searching reference lists. Subsequently, we add more than 150 con-
ference papers to the screening three-step procedure. ConClusions: The use of 
modelling is promising in this context. It can be explained by the required features 
of any early cost-effectiveness evaluation seeking to inform decision making. We 
aimed at distinguishing from the previous works, addressing this methodology. It 
should be stressed the very small amount of the papers on the topic. In addition, 
we highlight the absence of ad-hoc checklist and coding to be used for the quality 
assessment of early model-based analyses and data extracted classification. This 
work also tries to advance in the definition of appropriate criteria to evaluate the 
reliability of the analysis in terms of impact on primary stakeholders.
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assessMent of validation of health-econoMics decision Models in 
inteRvention studies of seasonal influenza and bReast canceR
de Boer PT1, Frederix GW2, Al MJ3, Feenstra TF4, Vemer P1
1University of Groningen, Groningen, The Netherlands, 2Utrecht University, Utrecht, The 
Netherlands, 3Erasmus University, Rotterdam, The Netherlands, 4University Medical Center 
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objeCtives: We aimed to review recently published health-economic (HE) decision 
models to assess the reporting of validation efforts. An infectious disease (seasonal 
influenza, SI) and a chronic disease (breast cancer, BC) were used as examples, 
giving a preliminary insight in the reporting of validation efforts in the overall HE 
literature. Methods: A literature search was performed in Pubmed and Embase 
to retrieve full-text HE modeling studies, published between 2008 and 2014. Type 
of evaluation, model and intervention were extracted, as well as information on 
model outcomes, journal and funding. Reporting on model validation was evalu-
ated by checking for the presence of the word validation and its conjugates, and 
by using AdViSHE, a tool which contains a structured list of relevant items for vali-
dation. Results: The literature search resulted in 53 SI and 45 BC studies. In 41 
studies (42%) the word validation or its conjugates was mentioned, but only in a 
small percentage in the context of model validation. The terminology used around 
validation was found to be ambiguous. Model validation efforts were reported in 
a minority of studies. However, some studies do show good reporting examples. 
Cross validation of study outcomes was reported most often, but the quantity and 
quality of this reporting varied. More validation efforts were reported in BC than 
in SI. ConClusions: Only a limited number of studies reported on model valida-
tion efforts, although it may be assumed that more efforts have been taken than 
were reported. In particular, the differences between SI and BC may not mean that 
less efforts were undertaken to validate SI models. Although validation is deemed 
important by many researchers, this is not reflected in the reporting habits of HE 
modeling studies. Better reporting of validation efforts would be desirable to further 
enhance decision-makers’ confidence in HE models and their outcomes.
PRM122
sensitivity analysis: how Much iMPact does it have on the nice 
decision Making PRocess?
Hirst A, Guy H, Murphy D
WG Access Ltd, London, UK
objeCtives: As part of economic evaluations submitted to NICE, probabilistic and 
deterministic sensitivity analysis are a requirement, with probabilistic sensitivity 
analysis being a stated preference in the NICE reference case. The aim of including 
sensitivity analysis is to identify the key areas of uncertainty, and determine the 
impact on results. The aim of this analysis was to assess what impact uncertainty 
in cost-effectiveness models has had on NICE reimbursement decisions and review 
what type of sensitivity analyses are conducted. Methods: The five most recent 
NICE appraisals for breast cancer were selected, the sensitivity analysis results 
and methods were extracted. Once extracted the results of the sensitivity analysis 
were compared and contrasted. The sensitivity analysis results were considered 
in the context of the base case results. Results: The methodology of sensitivity 
analysis conducted varied between submissions, whilst all appraisals conducted 
univariate sensitivity analysis only two reported tornado diagrams. The method 
of reporting results also varied between appraisals, of the four appraisals that had 
more than one comparator in the base case, only one appraisal conducted a multi-
way cost-effectiveness acceptability analysis. ConClusions: There are many fac-
tors that impact a NICE committees decision, therefore it is not possible to draw a 
conclusion on how the uncertainty impacted the decision making process. Of the 
appraisals assessed, there was a wide range of differences between deterministic 
and probabilistic ICERs, however it appears that this did not impact the appraisal. 
The sensitivity analysis reported across NICE submissions lacks consistency in the 
observed sample, hindering the comparison between submissions.
PRM123
how to Model suRvival in cost-effectiveness analysis? diffeRences 
between MaRkov and PaRtitioned suRvival analysis Models
Minacori R1, Bonastre J2, Lueza B2, Marguet S2, Levy P1
1Université Paris-Dauphine, Paris, France, 2Gustave Roussy, Villejuif, France
objeCtives: The choice of a modeling approach is guided by key criteria including 
time, interaction between individuals, and the unit of analysis (cohort or individuals 
level models). Despite Markov cohort modeling (MCM) is widely used in the litera-
ture, the use of partitioned survival (PS) models tends to increase. Our objective is 
to explore the rationale for selecting either a Markov modeling approach or a PS 
approach to carry-out a cost-effectiveness analysis in oncology. Our study focuses 
on the differences between the two approaches. Methods: A literature review 
focusing on survival modeling in economic evaluation was performed in order to 
establish a list of differences between the two modeling approaches. Besides, we 
reviewed NICE’s technology appraisals (TA) in oncology medicines over the last two 
years (2013-2015) to analyze the practices and the arguments put forward to justify 
modeling choices. Data collected for each TA included: model type, rationale for 
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of ischemic stroke moderate and severe degrees of severity using a drug cerebroly-
sin compared with standard therapy, cost-effectiveness ratios (CER) were obtained 
419656 RUB (6920 EUR) and 563183 RUB (9287 EUR), respectively. ConClusions: The 
standard therapy in combination with drug cerebrolysin has a lower CER compared 
with standard therapy, therefore, it is a dominant technology from the perspective 
of the cost-effectiveness analysis.
PRM130
using Machine leaRning to detect Patients with undiagnosed RaRe 
diseases: an aPPlication of suPPoRt vectoR Machines to a RaRe 
oncology disease
Rigg J, Lodhi H, Nasuti P
IMS Health, London, UK
objeCtives: Diagnostic algorithms to detect undiagnosed patients with rare dis-
eases have the potential to improve patient health and reduce costs associated 
with misdiagnosis. Accurate algorithms are difficult to develop, typically having 
to overcome Challenges including the tendency for models to I) over-fit, arising 
from low degrees of freedom / high-dimensionality and II) under-predict the rare 
disease, arising from the low ratio of confirmed to unconfirmed cases (skewed 
outcome class distribution). Support Vector Machines (SVMs) are a highly successful 
class of machine learning algorithms with well-established methods for handling 
high-dimensionality and skewed outcome class distribution. SVMs therefore rep-
resent a promising method to detect patients with undiagnosed rare diseases. This 
study estimated risk scores for a rare oncology disease using SVMs. The perfor-
mance of the models was compared to classical methods based on logistic regres-
sions. Methods: Risk scores for confirmed diagnosis were estimated with logistic 
regressions (standard, weighted and Firth) and SVMs (regularization, weights and 
kernel parameters were optimized using internal cross-validation). Patients with 
high risk scores and without a confirmed diagnosis have a higher probability of 
being undiagnosed cases. Model development, validation and testing were carried 
out on separate random samples from linked primary and secondary care data in 
the UK (Clinical Practice Research Datalink and Hospital Episode Statistics). The 
key performance metric was maximizing Sensitivity at a Positive Predicted Value 
(PPV) of 10% based on test data. Results: 334 confirmed cases were identified from 
approximately 1 million total cases. For a PPV of 10%, the Sensitivity for the best 
performing logistic regression (standard with no weights) and SVM (RBF kernel) was 
44% and 58% respectively on test data. ConClusions: SVMs represent a promising 
method for detecting undiagnosed patients with rare diseases, out-performing more 
conventional approaches based on logistic regressions. Greater adoption of these 
methods for this purpose is encouraged.
PRM131
health econoMic PRogRaMMing using Royston-PaRMaR “hazaRd 
Rate” Models: PRoviding flexibility and sPeed foR event Modelling 
in cohoRt and des Models
Kay SW, Kay JF
Model Outcomes Ltd, Cheshire, UK
objeCtives: Many diseases (e.g. oncology) display changing hazard rates over time 
that conventional parametric methods cannot replicate accurately. Various “flexible 
parametric” methods exist with increased number of parameters to alleviate this 
problem (Generalised Gamma and Generalised F distributions being examples). 
Royston-Parmar Hazard Rate Models (RPHRM) differ in one crucial regard – all key 
survival statistics (survival probability, cumulative hazard and hazard rate) can 
be calculated in closed form. This makes them ideal for HE models where speed 
of calculation is essential. It is relatively straight-forward to program such mod-
els in R to represent competing risks, non-proportional hazard ratios, adding RCT 
obtained hazard ratios to observational study standard of care baseline hazard esti-
mates, and extrapolation under various scenarios. All of this is possible under both 
Semi-Markov Cohort and Patient Level Discrete Event Simulation, DES, modelling. 
We display theory and R example code that illustrates these features. Methods: 
Publicly available example datasets were analysed using RPHRM within Stata (ado 
stpm2) under a maximum likelihood framework (Bayesian MCMC methods could 
be programmed). Parameters obtained were entered into various R functions. Key 
functions were those that derived the restricted cubic spline basis (and its deriva-
tive) associated with log time and its interaction with covariates deemed to have 
time varying effects. For DES modelling a Newton-Raphson algorithm was simple 
to program to generate event times. Competing risks were modelled by numeric 
integration (trapezium rule) to generate cumulative incidence functions from cause-
specific hazards using established formula. Results: Models were able to repli-
cate the real features of the inputted data. Output was validated against published 
results. PSA was conducted successfully and quickly. Required R functions were 
relatively short. ConClusions: RPHRM is the most suitable of “flexible parametric” 
survival models for HE modelling. It can represent any baseline hazard and hazard 
ratio time path without requiring time-consuming calculations.
PRM132
conditional coPula Models with aPPlications to bioMaRkeRs in 
RheuMatoid aRthRitis
Rakonczai P1, Rojkovich B2, Gáti T2
1Healthware Consulting Ltd., Budapest, Hungary, 2Buda Hospital of Hospitaller Brothers of St. 
John, Budapest, Hungary
objeCtives: Rheumatoid arthritis (RA) is a chronic autoimmune disease that 
causes pain, stiffness and limited motion and function of joints. There are several 
biomarkers (HAQ,VAS,DAS28) known for measuring disease activity from different 
point of views. The main objective is to investigate the association among them 
based on advanced statistical methods. Methods: Different biomarkers of 489 
RA patients were collected in one of the largest Arthritis Center in Hungary from 
5th Jun 1998 to 27th Feb 2015. Copula models are simple yet powerful tools for 
modeling joint distribution of multivariate variables. There are several parametric 
gain. Microsimulation and Markov cohort models use simpler models with aver-
age annual HAQ progression rates that can differ between treatments. A few of the 
Markov cohort models treat disease progression as separate states of the DAS28 
and estimate transition probabilities between such states over time. Disease pro-
gression of a radiographic score was modelled in one study, assuming a decreased 
deterioration of the radiographic score while being on treatment. No study modeled 
the impact of disease progression models on ACR response criteria. Finally, the two 
reviews did not include any cost-effectiveness analysis using decision trees that 
contained a disease progression model. ConClusions: Health economic decision 
models in RA include disease progression predominantly through the HAQ score. 
The impact of disease progression on discrete outcomes such as ACR20/50/70 is 
rarely considered in health economic models in RA.
PRM127
the futility of cost-efficacy analysis
Elbasha EH, Cook J
Merck & Co., Inc., Kenilworth, NJ, USA
objeCtives: Cost-efficacy analysis (CEA) (e.g., cost per cure or short-term 
response) is increasingly being used as an alternative or a supplement to cost-util-
ity analyses (CUA) employing the incremental cost per quality-adjusted life-year 
(QALY) gained. The objective of this study was to investigate whether conclu-
sions drawn from such CEAs were consistent with those of the gold standard 
CUA. Methods: We developed a model comparing standard of care (SOC) with 
a new drug. At the end of therapy, patients incurred short-term costs and either 
achieved a response or not. Non-responders incurred additional long-term costs 
and lost additional QALYs compared with responders. We evaluated two scenarios. 
In Scenario A: the short-term cost was $40,000 and efficacy was 65% with SOC. 
Drug cost and efficacy were $50,000 and 90%, respectively. For responders, the 
long-term cost offsets were $10,000 and additional QALYs were 0.5. Scenario B 
differed from Scenario A in only two aspects: the drug was more costly ($60,000), 
and the additional QALYs were higher (2.0 QALYs). We computed average cost-
efficacy ratio (ACER), incremental cost-efficacy ratio (ICER), and incremental cost-
utility ratio (ICUR). The assumed threshold for cost-effectiveness was $50,000/
QALY. Results: We found that a lower ACER than SOC was neither necessary 
(Scenario A: $66,667 vs $61,539/responder and ICUR= $35,000/QALY) nor sufficient 
(Scenario B: $55,556 vs $61,539/responder and ICUR= $60,000/QALY) for a more 
efficacious drug to be considered cost effective. Although the drug had a higher 
ICER in Scenario A ($80,000 per additional responder) than Scenario B ($40,000/
responder), the drug was cost-effective in Scenario A, and not so in Scenario B. 
We derived a formula that related ICER to ICUR. ConClusions: A lower average 
or incremental cost-efficacy ratio from a CEA was neither a necessary nor a suf-
ficient condition for a new drug to be considered cost effective compared with 
SOC based on a CUA.
PRM128
the liMitations of iceRs in scReening inteRventions and the 
Relative net benefit alteRnative
O’Mahony JF
Trinity College Dublin, Dublin, Ireland
objeCtives: To demonstrate the limitations of the incremental cost-effectiveness 
ratio (ICER) as a measure of improved cost-effectiveness in the context of periodic 
screening and to propose a new measure based on net benefit that quantifies the 
proportional gain in cost-effectiveness relative to the status quo. Methods: We 
use published cost-effectiveness estimates of cervical cancer screening to show why 
the ICER is not an appropriate measure of improvement in cost-effectiveness when 
screening performance improves, either through enhanced test characteristics or 
better risk stratification. We then propose a new metric based on the net health 
benefit measure previously devised by Stinnett and Mullahy. Results: It is shown 
how an improvement in screening may enhance cost-effectiveness, represented by 
an outward shift of the efficient frontier in the cost-effectiveness plane, but that 
this improvement is not necessarily reflected in the ICER. This is because the whole 
efficient frontier may shift when all strategies are affected by a common technologi-
cal change, and so ICERs on the frontier can be insensitive to this improvement. It 
is also shown that the ratio of costs to effects of a given strategy before and after 
a technological improvement also does not provide a useful measure of improved 
cost-effectiveness. The alternative measure of the proportional increase in net 
health benefit following the adoption of a new technology is then demonstrated. 
This metric quantifies the increase in net health benefit resulting from the new 
technology over a range of threshold values. ConClusions: ICERs will remain 
important for the identification of optimal intervention strategies. However, they are 
not suited for all circumstances. The net benefit alternative proposed here is a sim-
ple quantification of improved cost-effectiveness. The results presented here most 
readily apply to screening interventions, but also have application in other cases in 
which a technological development enhances multiple strategies simultaneously.
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cost-effectiveness analysis of ceRebRolysin in the tReatMent of 
Patients with acute ischeMic stRoke ModeRate and seveRe degRees 
of seveRity in the Russian fedeRation
Kulikov A, Abdrashitova G
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To estimate the cost-effectiveness of neurotrophic and neuroprotec-
tive drug cerebrolysin as treatment for patients with ischemic stroke of moderate 
and severe degrees of severity for one year. Methods: Information retrieval was 
conducted in the public domain. We used the pharmacoeconomic analysis method 
– cost-effectiveness analysis and analysis of the direct and indirect costs. For refer-
ence, we accepted the exchange rate was 1 EUR = 60,64 RUB. Results: In this study 
the life-years gained (LYG) was used as a criterion of the efficiency. During the cost-
effectiveness analysis we have found that the cost of one LYG less for the therapy 
